Suppr超能文献

COVID-19 患者的心血管疾病:从心血管病理学到治疗的证据。

Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.

机构信息

The Department of Cardio-thoracic Surgery, Hunan Children's Hospital, Changsha 410007, China.

Guangxi Key Laboratory of Diabetic Systems Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin 541100, China.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):273-282. doi: 10.1093/abbs/gmaa176.

Abstract

The coronavirus disease-2019 (COVID-19) caused by the novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly developed into a global pneumonia pandemic. Cardiovascular disease is the major comorbidity of COVID-19 patients and is closely related to the severity of COVID-19. SARS-CoV-2 infection can directly or indirectly cause a series of cardiac complications, including acute myocardial injury and myocarditis, heart failure and cardiac arrest, arrhythmia, acute myocardial infarction, cardiogenic shock, Takotsubo cardiomyopathy, and coagulation abnormalities. Intensive research on the SARS-CoV-2-associated cardiovascular complications is urgently needed to elucidate its exact mechanism and to identify potential drug targets, which will help to formulate effective prevention and treatment strategies. Hence, this review will summarize recent progress regarding the effects of COVID-19 on the cardiovascular system and describe the underlying mechanism of cardiovascular injury caused by SARS-CoV-2.

摘要

由新型冠状病毒严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)迅速发展为全球肺炎大流行。心血管疾病是 COVID-19 患者的主要合并症,与 COVID-19 的严重程度密切相关。SARS-CoV-2 感染可直接或间接引起一系列心脏并发症,包括急性心肌损伤和心肌炎、心力衰竭和心搏骤停、心律失常、急性心肌梗死、心源性休克、心尖球囊综合征和凝血异常。迫切需要对 SARS-CoV-2 相关心血管并发症进行深入研究,以阐明其确切机制并确定潜在的药物靶点,这将有助于制定有效的预防和治疗策略。因此,本综述将总结 COVID-19 对心血管系统的影响,并描述 SARS-CoV-2 引起心血管损伤的潜在机制。

相似文献

1
Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment.
Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):273-282. doi: 10.1093/abbs/gmaa176.
2
Cardiac Involvement of COVID-19: A Comprehensive Review.
Am J Med Sci. 2021 Jan;361(1):14-22. doi: 10.1016/j.amjms.2020.10.002. Epub 2020 Oct 6.
3
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
4
Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.00912-2020. Print 2020 Jul.
7
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Med Hypotheses. 2021 Jan;146:110452. doi: 10.1016/j.mehy.2020.110452. Epub 2020 Dec 9.
8
COVID-19 and Cardiovascular Disease.
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
9
COVID-19 and cardiovascular diseases.
J Mol Cell Biol. 2021 Jul 6;13(3):161-167. doi: 10.1093/jmcb/mjaa064.
10
COVID-19 and cardiovascular disease.
Clin Investig Arterioscler. 2020 Nov-Dec;32(6):263-266. doi: 10.1016/j.arteri.2020.10.005.

引用本文的文献

1
A Potential Therapeutic Effect of Suxiao Jiuxin Pills in Treating Postacute Sequelae of COVID-19: Case Report.
Case Rep Infect Dis. 2024 Nov 21;2024:4713552. doi: 10.1155/crdi/4713552. eCollection 2024.
3
Coronary Implications of COVID-19.
Med Princ Pract. 2025;34(1):1-12. doi: 10.1159/000541553. Epub 2024 Sep 20.
4
COVID-19 and the risk of acute cardiovascular diseases: a two-sample Mendelian randomization study.
BMC Cardiovasc Disord. 2024 Jul 27;24(1):389. doi: 10.1186/s12872-024-04066-9.
6
Ginseng and ginsenosides on cardiovascular and pulmonary diseases; Pharmacological potentials for the coronavirus (COVID-19).
J Ginseng Res. 2024 Mar;48(2):113-121. doi: 10.1016/j.jgr.2023.10.002. Epub 2023 Nov 2.
8
Echocardiography and laboratory outcomes of COVID-19 in children with a history of Kawasaki disease: a preliminary observation.
Front Cardiovasc Med. 2023 Oct 4;10:1127892. doi: 10.3389/fcvm.2023.1127892. eCollection 2023.
9
Common pathological findings in the heart in COVID-19-related sudden death cases: An autopsy case series.
Heliyon. 2023 Oct 2;9(10):e20564. doi: 10.1016/j.heliyon.2023.e20564. eCollection 2023 Oct.
10
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review.
Curr Atheroscler Rep. 2023 Oct;25(10):643-652. doi: 10.1007/s11883-023-01138-7. Epub 2023 Aug 30.

本文引用的文献

1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19.
Circ Heart Fail. 2020 Oct;13(10):e007485. doi: 10.1161/CIRCHEARTFAILURE.120.007485. Epub 2020 Aug 26.
3
Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic.
JAMA Netw Open. 2020 Jul 1;3(7):e2014780. doi: 10.1001/jamanetworkopen.2020.14780.
4
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Biochem Pharmacol. 2020 Aug;178:114114. doi: 10.1016/j.bcp.2020.114114. Epub 2020 Jun 21.
5
Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study.
Crit Care. 2020 May 14;24(1):219. doi: 10.1186/s13054-020-02939-x.
6
[Management of COVID-19: the Zhejiang experience].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(2):147-157. doi: 10.3785/j.issn.1008-9292.2020.02.02.
7
COVID-19 and its implications for thrombosis and anticoagulation.
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
8
SARS-CoV-2 and viral sepsis: observations and hypotheses.
Lancet. 2020 May 9;395(10235):1517-1520. doi: 10.1016/S0140-6736(20)30920-X. Epub 2020 Apr 17.
9
The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome.
J Thromb Haemost. 2020 Jul;18(7):1747-1751. doi: 10.1111/jth.14854. Epub 2020 May 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验